Physician profile
Wasil Khan
NPI 1104828250
$6,847.65
in general payments reported to CMS, 2019-2025
35 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $238 · 2021: $140 · 2022: $974 · 2023: $1,141 · 2024: $1,792 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,981 · Education: $45.66 · Consulting Fee: $25.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,980.96 |
| Education | $45.66 |
| Consulting Fee | $25.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,389.68 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Biocryst US Sales Co., LLC | $1,257.09 | 2022-2025 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $868.06 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Pfizer INC. | $556.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $490.53 | 2022-2025 | Cuvitru, Takhzyro, Glassia |
| Regeneron Healthcare Solutions, INC. | $478.19 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $414.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $213.11 | 2019-2025 | |
| Grifols USA, LLC | $181.26 | 2020-2024 | Xembify |
| Amgen INC. | $137.17 | 2022-2025 | Tezspire |
| Genzyme Corporation | $105.60 | 2022-2025 | |
| Ionis Pharmaceuticals, INC. | $90.54 | 2025 | Dawnzera |
| Alk-Abello, INC | $87.04 | 2019-2025 | Ragwitek, Odactra, Grastek |
| Blueprint Medicines Corporation | $65.21 | 2024 | Ayvakit |
| Pharming Healthcare, INC. | $48.47 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $37.93 | 2025 | Neffy |
| Cycle Pharmaceuticals INC | $37.51 | 2025 | Sajazir |
| Dexcom, INC. | $30.78 | 2025 | Dexcom G6 Transmitter |
| Kaleo, INC. | $28.58 | 2019-2020 | |
| Octapharma USA, INC. | $25.92 | 2019 | |
| Adma Biomanufacturing LLC | $25.78 | 2025 | |
| Hospira, INC. | $24.95 | 2023 | |
| Optinose US, INC. | $24.79 | 2025 | |
| Genentech USA, INC. | $24.10 | 2024 | Xolair |
| Merck Sharp & Dohme LLC | $23.89 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2024 | Ofev |
| Hikma Pharmaceuticals USA | $21.67 | 2024 | Ryaltris |
| Abbvie INC. | $20.98 | 2024 | |
| Lilly USA, LLC | $19.26 | 2022 | |
| Circassia INC. | $18.54 | 2019 | |
| Gc Biopharma USA, INC. | $18.18 | 2024 | Alyglo |
| Exact Sciences Corporation | $16.93 | 2025 | Cologuard Collection Kit |
| Shire North American Group INC | $14.79 | 2019 | |
| Mannkind Corporation | $14.72 | 2022 | |
| Galderma Laboratories, L.P. | $14.10 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasil Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.